Interna Therapeutics is an innovative biotechnology company that developed a transformational delivery technology for macromolecules. The pioneering technology, named Molecular Nano-Motors (MNMs), is based on a novel mechanism that leverages membrane electrical forces, facilitating entry of charged molecules into cells. With this technology new treatment options become available for a wide range of diseases using difficult to deliver molecules such as oligonucleotide-based drugs (siRNA, ASO). Equipped with full-capacity research facilities and working with leading research organizations, the team of seasoned scientists has demonstrated the therapeutic potential of MNM technology in numerous preclinical studies, with a Phase I study of a COVID-19 drug that began in September 2024. Interna’s innovative spirit and scientific excellence has been recognized by key opinion leaders in the pharma industry and by non-governmental organizations.